Fortress Biotech (FBIO) & Its Peers Head-To-Head Contrast

Fortress Biotech (NASDAQ:FBIO) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Fortress Biotech to similar businesses based on the strength of its dividends, analyst recommendations, risk, institutional ownership, profitability, valuation and earnings.

Earnings and Valuation

This table compares Fortress Biotech and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fortress Biotech	$63.26 million	$6.82 million	0.71
Fortress Biotech Competitors	$3.55 billion	$3.18 billion	561.70

Fortress Biotech’s rivals have higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings for Fortress Biotech and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1	1	2	0	2.25
Fortress Biotech Competitors	7840	13794	25805	1039	2.41

Fortress Biotech presently has a consensus target price of $17.00, suggesting a potential upside of 804.26%. As a group, “Pharmaceuticals” companies have a potential upside of 24.63%. Given Fortress Biotech’s higher probable upside, equities research analysts clearly believe Fortress Biotech is more favorable than its rivals.

Profitability

This table compares Fortress Biotech and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Fortress Biotech Competitors	-2,400.69%	-221.80%	-15.58%

Volatility and Risk

Fortress Biotech has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Fortress Biotech’s rivals have a beta of -0.13, meaning that their average stock price is 113% less volatile than the S&P 500.

Insider and Institutional Ownership

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Fortress Biotech beats its rivals on 7 of the 13 factors compared.

Fortress Biotech Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.